KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$39568.0.

  • Co-Diagnostics' Non Operating Income fell 10705.73% to -$39568.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 1591.04%. This contributed to the annual value of $2.5 million for FY2024, which is 4560.82% down from last year.
  • According to the latest figures from Q3 2025, Co-Diagnostics' Non Operating Income is -$39568.0, which was down 10705.73% from $339974.0 recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Non Operating Income registered a high of $3.3 million during Q1 2022, and its lowest value of -$450286.0 during Q1 2021.
  • For the 5-year period, Co-Diagnostics' Non Operating Income averaged around $848941.5, with its median value being $837294.0 (2023).
  • In the last 5 years, Co-Diagnostics' Non Operating Income crashed by 278731.2% in 2021 and then soared by 581295.35% in 2022.
  • Quarter analysis of 5 years shows Co-Diagnostics' Non Operating Income stood at -$64434.0 in 2021, then skyrocketed by 1771.38% to $1.1 million in 2022, then dropped by 8.74% to $982760.0 in 2023, then fell by 11.71% to $867657.0 in 2024, then plummeted by 104.56% to -$39568.0 in 2025.
  • Its Non Operating Income was -$39568.0 in Q3 2025, compared to $339974.0 in Q2 2025 and $1.0 million in Q1 2025.